Author + information
- Eric J. Topol, MD, FACC∗,a,
- Robert M. Califf, MD, FACC†,
- Barry S. George, MDc,
- Dean J. Kereiakes, MD, FACCd,
- Kerry L. Lee, PhDb,
- The Tami Study Group∥
- ↵∗Address for reprints: Eric J. Topol, MD, Division of Cardiology, University of Michigan Medical Center, B1 F245, 1500 East Medical Center Drive, Ann Arbor, Michigan 48109-0022.
In the first three phases of Thrombolysis and Angioplasty in Myocardial Infarction (TAMI) multicenter trials, 708 patients received intravenous recombinant tissue-type plasminogen activator (rt-PA) and underwent detailed assessment of clinical, angiographic and ventriculographic outcomes. The cumulative experience and data base afford the opportunity to address several important questions regarding aggressive therapy of myocardial infarction. These include predictive factors of in-hospital mortality, improvement of left ventricular function and the occurrence of recurrent ischemia.
Consideration of practical issues, such as thrombolytic therapy for patients with cardiopulmonary resuscitation or previous stroke, use of coronary artery bypass surgery and the effect of operator experience on angioplasty success rate, has also been made possible. The major accomplishments as well as the deficiencies of the current approach to patient management after thrombolysis are reviewed, and the new TAMI trials currently underway are discussed.